Juvena Therapeutics

juvenatherapeutics.com

Juvena Therapeutics is a computationally-driven biopharmaceutical company focused on researching, developing, and commercializing tissue restorative biologics to treat myopathies and metabolic diseases. Utilizing an AI-enabled platform, Juvena maps the therapeutic potential of secreted proteins and engineers them into biologics that restore tissue homeostasis. Their lead asset, JUV-161, is in IND-enabling studies for Myotonic Dystrophy Type 1, with additional programs targeting obesity, sarcopenia, and other metabolic diseases. The company aims to pioneer treatments that address chronic diseases and promote healthy aging, positioning itself as a leader in the biopharmaceutical space.